New approaches needed to mitigate impact of HLA mismatch in bone marrow transplantation
Healio spoke with Heather Stefanski, MD, PhD, for a three-part video series about trends in the field of bone marrow transplantation.
In this video, Stefanski — vice president of medical services for National Marrow Donor Program/Be The Match — highlights the lack of equality in access to a potentially lifesaving transplant based on ethnicity.
“We need to develop new approaches to transplant that mitigate the impact of HLA mismatches,” Stefanski told Healio.
As part of that effort, Stefanski provides an overview of the 15-MMUD study — designed to evaluate OS after HLA-mismatched unrelated donor bone marrow transplantation — and previews the ACCESS trial, which will evaluate OS at 1 year following transplantation of a peripheral blood stem cell product from a mismatched unrelated donor using post-transplant cyclophosphamide as graft-versus-host disease prophylaxis.